A series of papers reviewing pulmonary exacerbations in CF and bronchiectasis

J S Elborn, S C Bell

In the current (see page 360) and forthcoming issues of *Thorax* we are publishing a series examining current practice and evidence of the epidemiology and pathogenesis, prevention and treatment of pulmonary exacerbations in patients with cystic fibrosis (CF) and bronchiectasis.14 This follows on from a recent series examining aspects of exacerbations of chronic obstructive pulmonary disease and asthma. These reviews involved authors from Australia, USA and the UK, and each has considered the topics from both a paediatric and adult perspective. Several themes emerge in these reviews, including: (1) the challenges of diagnostic precision of definitions of respiratory exacerbations; (2) the need to develop new and/or novel endpoints for therapeutic trials for the treatment of exacerbations; and (3) the urgent need for multicentre studies to investigate both preventive and therapeutic interventions for patients with CF and bronchiectasis.

Goss and Burns highlight recent studies which have used definitions of...
pulmonary exacerbations in patients with CF. While many of the multicentre studies have used formal definitions of exacerbations, all have included components which are subjective and have had only limited validation. Even the role of objective clinical measures in the definition of exacerbations, such as pulmonary function, has been questioned. Two diagnostic scores have been recent useful additions for use in therapeutic trials, but further validation is required before they can be widely applied. Chang and Bilton highlight the fact that very limited information is currently available on the definition of pulmonary exacerbations in patients with bronchiectasis.

Until recently the change in forced expiratory volume in 1 s has been the primary endpoint for most CF therapeutic trials. Improved median survival and reduction in the rate of decline of pulmonary function suggest improvement in the outcomes for patients with CF. Consequently, either larger study populations or longer clinical trials will be required to provide data to support the role of new treatments, if these classic trial endpoints are to continue to be used. As a result, new endpoints for trials have emerged, including changes in quality of life and changes in the rates of and time to pulmonary exacerbation.

The inclusion of the latter two further highlights the need for more research on the validity of scoring systems to define respiratory exacerbations.

Evidence-based advances in the management of patients with CF have been seen in the past decade with the successful completion of numerous multicentre clinical trials. These studies have confirmed the role of mucolytics and hypertonic saline, inhaled antibiotics (such as tobramycin), anti-inflammatory therapies and macrolides in improving clinical outcomes, including in some cases the effects on exacerbation rates highlighted in the review by Bell and Robinson. Furthermore, it is now clear that parenteral aminoglycosides (such as tobramycin) for the treatment of pulmonary exacerbations may be better administered by once daily dosing than by multiple daily doses. Such evidence has led to major changes in practice for patients with CF. However, each of the reviews highlights significant gaps in the knowledge of many aspects of the treatment of patients with CF and bronchiectasis.

While there are now some data supporting treatment choices for the most common bacterial pathogen in patients with CF (Pseudomonas aeruginosa), more study is required to extend the limited in vitro data to support antibiotic choices for less common and often more resistant pathogens such as Burkholderia cepacia complex, Stenotrophomonas maltophilia, Acinetobacter species and methicillin-resistant Staphylococcus aureus in patients with CF. Such studies will require a collaborative and international approach to draw together sufficient patient numbers to provide study power and thus are likely to be extremely difficult to fund. Similarly, further study is required to examine treatment choices for very young children with CF which, to date, have received more limited attention in multicentre therapeutic studies.

There are also very few data currently available comparing the role of different treatments, both with each other and as complementary therapies. For example, we do not know whether rhDNase 1 is more effective than hypertonic saline or whether the effect of rhDNase 1 is enhanced by the administration of hypertonic saline to the same patient, or whether such combinations are counterproductive for some patients. Given that current clinical practice has often involved the addition of a new treatment modality to existing therapies, it is hoped that such comparisons could be performed in the future, particularly as many new treatments are expensive for our healthcare systems and/or are time-consuming for the patient.

Even more work remains to be performed to provide evidence to support treatment choices for patients with bronchiectasis. Most studies of preventive and treatment strategies of respiratory exacerbations in bronchiectasis have been undertaken at a single centre and have included small patient numbers where power calculations have not been reported and where the definitions of exacerbations have been limited. An important message of the study by O'Donnell et al.—who reported the results of a randomised controlled trial to assess the effect of rhDNase 1 in patients with idiopathic bronchiectasis—was that, while rhDNase 1 is an effective treatment in patients with CF, these benefits are not directly transferable to patients with bronchiectasis.

Studies addressing a specific treatment need to be performed in patients with bronchiectasis. The recent publication of the characteristics of a cohort of patients with bronchiectasis provides an opportunity to draw together clinicians and researchers with an interest in this understudied disease to allow the design, search for funding support and successful execution of multicentre studies. However, funding bodies will need to take a far-reaching view and to look for improved patient outcomes by evidence-based treatment strategies, as is starting to be realised for patients with CF.

Exacerbations of CF and bronchiectasis have a negative impact on patients' quality of life, require expensive treatment and are associated with poor outcomes. Finding ways to reduce the frequency of these events will improve the lives of people with chronic suppurative lung disease.

**Editors' notes**

Based on the current literature, the management of exacerbations remains a major challenge. Although the role of rhDNase 1 in patients with CF has been questioned, it is clear that parenteral aminoglycosides have been beneficial in treating pulmonary exacerbations in patients with bronchiectasis. Further validation is required before these new endpoints are to continue to be used. Evidence-based advances in the management of patients with CF have been seen in the past decade with the successful completion of numerous multicentre clinical trials. These studies have confirmed the role of mucolytics and hypertonic saline, inhaled antibiotics (such as tobramycin), anti-inflammatory therapies and macrolides in improving clinical outcomes, including in some cases the effects on exacerbation rates highlighted in the review by Bell and Robinson. Furthermore, it is now clear that parenteral aminoglycosides (such as tobramycin) for the treatment of pulmonary exacerbations may be better administered by once daily dosing than by multiple daily doses. Such evidence has led to major changes in practice for patients with CF. However, each of the reviews highlights significant gaps in the knowledge of many aspects of the treatment of patients with CF and bronchiectasis.

While there are now some data supporting treatment choices for the most common bacterial pathogen in patients with CF (Pseudomonas aeruginosa), more study is required to extend the limited in vitro data to support antibiotic choices for less common and often more resistant pathogens such as Burkholderia cepacia complex, Stenotrophomonas maltophilia, Acinetobacter species and methicillin-resistant Staphylococcus aureus in patients with CF. Such studies will require a collaborative and international approach to draw together sufficient patient numbers to provide study power and thus are likely to be extremely difficult to fund. Similarly, further study is required to examine treatment choices for very young children with CF which, to date, have received more limited attention in multicentre therapeutic studies.

There are also very few data currently available comparing the role of different treatments, both with each other and as complementary therapies. For example, we do not know whether rhDNase 1 is more effective than hypertonic saline or whether the effect of rhDNase 1 is enhanced by the administration of hypertonic saline to the same patient, or whether such combinations are counterproductive for some patients. Given that current clinical practice has often involved the addition of a new treatment modality to existing therapies, it is hoped that such comparisons could be performed in the future, particularly as many new treatments are expensive for our healthcare systems and/or are time-consuming for the patient.

Even more work remains to be performed to provide evidence to support treatment choices for patients with bronchiectasis. Most studies of preventive and treatment strategies of respiratory exacerbations in bronchiectasis have been undertaken at a single centre and have included small patient numbers where power calculations have not been reported and where the definitions of exacerbations have been limited. An important message of the study by O'Donnell et al.—who reported the results of a randomised controlled trial to assess the effect of rhDNase 1 in patients with idiopathic bronchiectasis—was that, while rhDNase 1 is an effective treatment in patients with CF, these benefits are not directly transferable to patients with bronchiectasis.

Studies addressing a specific treatment need to be performed in patients with bronchiectasis. The recent publication of the characteristics of a cohort of patients with bronchiectasis provides an opportunity to draw together clinicians and researchers with an interest in this understudied disease to allow the design, search for funding support and successful execution of multicentre studies. However, funding bodies will need to take a far-reaching view and to look for improved patient outcomes by evidence-based treatment strategies, as is starting to be realised for patients with CF.

Exacerbations of CF and bronchiectasis have a negative impact on patients' quality of life, require expensive treatment and are associated with poor outcomes. Finding ways to reduce the frequency of these events will improve the lives of people with chronic suppurative lung disease.

**Authors’ affiliations**

J Elborn, Respiratory Medicine Research Group, Queens University of Belfast and Adult CF Centre Belfast City Hospital, Belfast BT9 7AB, UK

C Bell, Adult Cystic Fibrosis Centre and School of Medicine, University of Queensland, The Prince Charles Hospital, Brisbane 4032, Australia

Correspondence to: Professor J Elborn, Adult CF Centre Belfast City Hospital, Belfast BT9 7AB, UK; Stuart.Elborn@bch.n-i.nhs.uk

Competing interests: None.

**REFERENCES**


8. Dodge JA, Lewis PA. Cystic fibrosis is no longer an important cause of childhood death in the UK. Arch Dis Child 2005;90:547.


BMJ Clinical Evidence—Call for contributors

BMJ Clinical Evidence is a continuously updated evidence-based journal available worldwide on the internet which publishes commissioned systematic reviews. BMJ Clinical Evidence needs to recruit new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence-based medicine, with the ability to write in a concise and structured way and relevant clinical expertise.

Areas for which we are currently seeking contributors:

- Secondary prevention of ischaemic cardiac events
- Acute myocardial infarction
- MRSA (treatment)
- Bacterial conjunctivitis

However, we are always looking for contributors, so do not let this list discourage you.

Being a contributor involves:

- Selecting from a validated, screened search (performed by in-house Information Specialists) valid studies for inclusion.
- Documenting your decisions about which studies to include on an inclusion and exclusion form, which we will publish.
- Writing the text to a highly structured template (about 1500–3000 words), using evidence from the final studies chosen, within 8–10 weeks of receiving the literature search.
- Working with BMJ Clinical Evidence editors to ensure that the final text meets quality and style standards.
- Updating the text every 12 months using any new, sound evidence that becomes available. The BMJ Clinical Evidence in-house team will conduct the searches for contributors; your task is to filter out high quality studies and incorporate them into the existing text.
- Expand the review to include a new question about once every 12 months. In return, contributors will see their work published in a highly-rewarded peer-reviewed international medical journal. They also receive a small honorarium for their efforts.

If you would like to become a contributor for BMJ Clinical Evidence or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to CECommissioning@bmjgroup.com.

Call for peer reviewers

BMJ Clinical Evidence also needs to recruit new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are healthcare professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity and accessibility of specific reviews within the journal, and their usefulness to the intended audience (international generalists and healthcare professionals, possibly with limited statistical knowledge).

Reviews are usually 1500–3000 words in length and we would ask you to review between 2–5 systematic reviews per year. The peer review process takes place throughout the year, and our turnaround time for each review is 10–14 days. In return peer reviewers receive free access to BMJ Clinical Evidence for 3 months for each review.

If you are interested in becoming a peer reviewer for BMJ Clinical Evidence, please complete the peer review questionnaire at www.clinicevidence.com/ceweb/contribute/peerreviewer.jsp